BIO.B vs. RPRX: Bio-Rad Laboratories vs. Royalty Pharma Stock Comparison
How do Bio-Rad Laboratories (BIO.B) and Royalty Pharma (RPRX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Bio-Rad Laboratories (BIO.B) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while RPRX is classified in Pharmaceuticals.
Bio-Rad Laboratories (BIO.B) has more than two decades of public-market history since September 21, 1999, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.
| Profile Item | BIO.B | RPRX |
|---|---|---|
| Name | Bio-Rad Laboratories, Inc. Class B Common Stock | Royalty Pharma plc Class A Ordinary Shares |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 10.49 billion USD | 38.70 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | September 21, 1999 | June 16, 2020 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| Total Return (1Y) | 27.69% | 81.08% |
| Total Return (3Y, Annualized) | 9.13% | 39.21% |
| Total Return (5Y, Annualized) | -12.33% | 14.22% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Royalty Pharma (RPRX) trades around 3.10M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.
| Metric | BIO.B | RPRX |
|---|---|---|
| Volatility (1Y, Annualized) | 30.96% | 22.05% |
| Beta (5Y) | 1.00 | 0.36 |
| Max Drawdown (5Y) | -70.74% | -41.98% |
| Avg. Volume (3M) | 11 | 3.10M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 3.48 |
| Sortino Ratio (1Y) | 1.10 | 5.72 |
Profitability
ROE (TTM)
Both Bio-Rad Laboratories (BIO.B) at 14.27% and Royalty Pharma (RPRX) at 12.09% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.27%
- Max
- 109.18%
- BIO.B
- 14.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.09%
- Max
- 109.18%
- RPRX
- 12.09%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Bio-Rad Laboratories (BIO.B) at 39.45% and Royalty Pharma (RPRX) at 25.70% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.45%
- BIO.B
- 39.45%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.70%
- RPRX
- 25.70%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Royalty Pharma (RPRX) at 81.32% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.46%
- Max
- 83.12%
- Q3
- 14.77%
- BIO.B
- 9.46%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.32%
- Max
- 83.12%
- RPRX
- 81.32%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| ROE (TTM) | 14.27% | 12.09% |
| ROA (TTM) | 1.50% | 5.43% |
| Net Margin (TTM) | 39.45% | 25.70% |
| Operating Margin (TTM) | 9.46% | 81.32% |
| Gross Margin (TTM) | 52.19% | 99.79% |
Growth
Revenue Growth
Both Bio-Rad Laboratories (BIO.B) at 0.65% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Royalty Pharma (RPRX) reports EPS growth of 23.09%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.
Growth Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| Revenue Growth (YoY) | 0.65% | 5.06% |
| Revenue Growth (3Y CAGR) | -2.68% | 2.06% |
| EPS Growth (YoY) | -- | 23.09% |
| EPS Growth (3Y CAGR) | -- | 161.10% |
Financial Strength
Current Ratio (MRQ)
Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Royalty Pharma (RPRX) at 1.29 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RPRX.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.18
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- BIO.B
- 3.18
- Q1
- 2.47
- Min
- 0.10
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.29
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- RPRX
- 1.29
- Min
- 0.10
Debt / Equity (MRQ)
Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while Royalty Pharma (RPRX) at 0.88 uses more debt funding than most peers.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.18
- Max
- 1.42
- Q3
- 0.65
- BIO.B
- 0.18
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.88
- Max
- 1.42
- RPRX
- 0.88
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| Current Ratio (MRQ) | 3.18 | 1.29 |
| Debt / Equity (MRQ) | 0.18 | 0.88 |
| Net Debt / EBITDA | -0.73 | 4.76 |
Dividends
Dividend Yield (TTM)
Bio-Rad Laboratories (BIO.B) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a yield of 1.37%, ranking against industry peers normally.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO.B
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.37%
- RPRX
- 1.37%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Bio-Rad Laboratories (BIO.B) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Royalty Pharma (RPRX) reports a payout of 60.46%, ranking against industry peers normally.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BIO.B
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
60.46%
- RPRX
- 60.46%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 1.37% |
| Dividend Payout Ratio (TTM) | 0.00% | 60.46% |
Valuation
P/E Ratio (TTM)
Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.36
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- BIO.B
- 10.36
- Min
- 0.07
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.99
- Max
- 85.34
- RPRX
- 43.99
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.05
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- BIO.B
- 4.05
- Q1
- 3.01
- Min
- 0.01
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.79
- Max
- 58.18
- Q3
- 25.77
- RPRX
- 14.79
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Royalty Pharma (RPRX) at 4.39 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.
BIO.B
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BIO.B
- 1.38
- Min
- -5.59
RPRX
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.39
- Max
- 13.53
- Q3
- 6.54
- RPRX
- 4.39
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BIO.B | RPRX |
|---|---|---|
| P/E Ratio (TTM) | 10.36 | 43.99 |
| P/S Ratio (TTM) | 4.05 | 14.79 |
| P/B Ratio (MRQ) | 1.38 | 4.39 |
| Free Cash Flow Yield (TTM) | 2.59% | -1.16% |